Results 11 to 20 of about 19,651 (218)

Effect of Cardiac Myosin Inhibitors on Echocardiographic Features of Cardiac Structure and Function in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. [PDF]

Rev Cardiovasc Med
Background: Recent advancements have introduced novel cardiac myosin inhibitors (CMIs) that have demonstrated significant efficacy in treating hypertrophic cardiomyopathy (HCM).
Lu Y, Zhu Y, Tian Z.
europepmc   +2 more sources

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Hypertrophic cardiomyopathy (HCM) represents the most common inherited cardiac disease and a leading cause of heart failure, arrhythmias, and sudden cardiac death in young individuals.
Sedaghat-Hamedani F, Kayvanpour E, Meder B.   +2 more
europepmc   +2 more sources

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis. [PDF]

Arch Med Sci Atheroscler Dis
Introduction Hypertrophic cardiomyopathy (HCM) is a common genetic cardiac disorder associated with significant morbidity and mortality. Cardiac myosin inhibitors (MIs), including mavacamten and aficamten, offer a novel therapeutic approach for HCM ...
Hazique M, Lohana S, Kafle S, Bhinder J, Patel KN, Basit J, Bahar AR, Kvapil J, Alraies MC.   +8 more
europepmc   +2 more sources

Cardiac myosin inhibitors in hypertrophic cardiomyopathy. [PDF]

J Cardiovasc Imaging
Lim J, Kim HK.
europepmc   +3 more sources

Precision Negative Inotropy: The Rise of Cardiac Myosin Inhibitors in HCM

Journal of Education, Health and Sport
Background: Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, marked by left-ventricular hypertrophy, dynamic outflow obstruction in many patients, diastolic dysfunction, and elevated risks of atrial fibrillation and heart ...
Katarzyna Skibicka, Tomasz Skibicki, Weronika Wesołowska, Robert Bujak   +3 more
openalex   +4 more sources

Incidence of Ventricular Arrhythmias and Sudden Cardiac Death with Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. [PDF]

J Pers Med
Katic J, Bulum T, Borovac JA.
europepmc   +3 more sources

Coexistence of Hypertrophic Cardiomyopathy and Arterial Hypertension: Current Insights and Future Directions. [PDF]

Diseases
Background: Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease. Arterial hypertension represents the leading modifiable risk factor for cardiovascular morbidity and mortality globally.
Katsi V, Papadomarkaki K, Manousiadis K, Triantafyllou E, Fragoulis C, Tsioufis K.   +5 more
europepmc   +2 more sources

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Hasana U, Korpal M, Haider F, Umer M, Lwin NPT, Iqbal S, Kumar R, Ahsan M, Hassan E, Ullah W, Khalid S, Gupta A, Alsubari AMA, Ehsan M, Ahmad A.   +14 more
europepmc   +2 more sources

Cardiac myosin inhibitors: a silver lining for an old disease. [PDF]

Open Heart
Yadav S, Agstam S, Singh S.
europepmc   +2 more sources

Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors. [PDF]

ESC Heart Fail
Erzeel J, Dhont S, van Es M, Ulgar D, Bertrand P, Mullens W, Martens P.   +6 more
europepmc   +2 more sources